Inclusion Criteria:  Laboratory confirmed (SARS-Cov-2 PCR-positive test) mild COVID-19 infection (in the last three days), COVID-19 patient in stable, moderate condition (i.e., not requiring Intensive Care Unit (ICU) admission). Subjects must be under observation or admitted to a controlled facility or hospital (home quarantine is not sufficient). Able to take medication alone Able to give informed consent.  Exclusion Criteria:  Pulmonary diseases Chronic pulmonary diseases Chronic rhinosinusitis Patient admitted already under invasive mechanical ventilation; The patient admitted with the severe acute respiratory syndrome and diagnosed with an etiologic agent other than Covid 19; Renal failure requiring dialysis or creatinine ≥ 2.0mg/dl; Tube feeding or parenteral nutrition. Respiratory decompensation requiring mechanical ventilation. Uncontrolled diabetes type 2. Hypertension stage 3, Autoimmune disease. Pregnant or lactating women. Patients are taking antibiotics for a reason other than COVID-19 at enrollment. Has a chronically weakened immune system (AIDS, lymphoma, chemo-radio- corticosteroid therapy, immunosuppressive pathology); Patients treated with chemo-radio-corticosteroid therapy in the last six months. Patients with active cancer. Taking immunosuppressive drugs (e.g., anti-rejection treatment after organ transplant); Already participating in another clinical trial; Has any other condition that would prevent safe participation in the study.